Alzheimer's Disease (AD) is a major international health problem with unknown etiology and pathogenesis. This program project grant unites a multidisciplinary group of clinical and basic scientists to address a number of etiologic or pathogenetic mechanisms in AD. A Core facility provides extraneural tissue from living AD patients or autopsied brain tissue from thoroughly evaluated and longitudinally followed AD patients. Project 1 will assay neuronotrophic factor alterations in AD and correlate these changes with classic AD morphological markers (NFT and SP). Cholinergic markers (CAT/AChE), using laminar microchemical techniques, will be directly correlated with morphological markers. Project 2 will study levels, precursors, metabolites and receptor binding of the monoaminergic system in the nucleus basalis of Meynert, hippocampus and cerebral cortex and correlate these with cholinergic markers and classic morphologic markers in AD. Project 3 will study brain trace element levels to define potential neurotoxic elements and/or imbalances in AD and control brains, utilizing instrumental and radiochemical neutron activation analyses, correlated with scanning electron microscopy microprobe analyses. Hair and fingernail trace element levels will be determined in AD patients followed longitudinally and in twins, one of whom has AD. Project 4 will define alterations in AD erythrocyte membrane cytoskeletal proteins utilizing electron spin resonance labeling. Choline efflux and transport properties of AD erythrocyte membranes will be studied to define an extraneural marker for AD. Project 5 will investigate protein synthesis in AD brains utilizing a cell free system and in situ labeling. The relationship of cap-binding protein to neurofilaments and NFT will be studied using immunocytochemical and immunoblotting techniques and the structure and properties of messenger RNA in AD and control will be compared. This program project grant, with the opportunity for correlative clinical, morphological and biochemical studies of longitudinally follow AD patients, offers the tremendous potential to further understanding of this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG005119-02
Application #
3090969
Study Section
Aging Review Committee (AGE)
Project Start
1984-12-01
Project End
1988-11-30
Budget Start
1985-12-01
Budget End
1986-11-30
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Type
Schools of Medicine
DUNS #
832127323
City
Lexington
State
KY
Country
United States
Zip Code
40506
Ding, Qunxing; Zhu, Haiyan (2018) Upregulation of PSMB8 and cathepsins in the human brains of dementia with Lewy bodies. Neurosci Lett 678:131-137
Ellison, Elizabeth M; Abner, Erin L; Lovell, Mark A (2017) Multiregional analysis of global 5-methylcytosine and 5-hydroxymethylcytosine throughout the progression of Alzheimer's disease. J Neurochem 140:383-394
Hartz, Anika M S; Zhong, Yu; Wolf, Andrea et al. (2016) A?40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway. J Neurosci 36:1930-41
Butterfield, D Allan; Palmieri, Erika M; Castegna, Alessandra (2016) Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Rev Proteomics 13:259-74
Bradley-Whitman, Melissa A; Lovell, Mark A (2015) Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. Arch Toxicol 89:1035-44
Barone, Eugenio; Cenini, Giovanna; Di Domenico, Fabio et al. (2015) Basal brain oxidative and nitrative stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53. J Neurosci Res 93:1728-39
Di Domenico, Fabio; Pupo, Gilda; Mancuso, Cesare et al. (2015) Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease. J Alzheimers Dis 44:1107-20
Chen, Chun-Hau; Li, Wenzong; Sultana, Rukhsana et al. (2015) Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiol Dis 76:13-23
Lovell, Mark A; Abner, Erin; Kryscio, Richard et al. (2015) Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production. Oxid Med Cell Longev 2015:787805
Sethi, M; Joshi, S S; Webb, R L et al. (2015) Increased fragmentation of sleep-wake cycles in the 5XFAD mouse model of Alzheimer's disease. Neuroscience 290:80-9

Showing the most recent 10 out of 244 publications